JP2022517407A5 - - Google Patents

Info

Publication number
JP2022517407A5
JP2022517407A5 JP2021541198A JP2021541198A JP2022517407A5 JP 2022517407 A5 JP2022517407 A5 JP 2022517407A5 JP 2021541198 A JP2021541198 A JP 2021541198A JP 2021541198 A JP2021541198 A JP 2021541198A JP 2022517407 A5 JP2022517407 A5 JP 2022517407A5
Authority
JP
Japan
Application number
JP2021541198A
Other languages
Japanese (ja)
Other versions
JPWO2020148548A5 (https=
JP2022517407A (ja
JP7587506B2 (ja
Filing date
Publication date
Priority claimed from GBGB1900702.0A external-priority patent/GB201900702D0/en
Application filed filed Critical
Publication of JP2022517407A publication Critical patent/JP2022517407A/ja
Publication of JPWO2020148548A5 publication Critical patent/JPWO2020148548A5/ja
Publication of JP2022517407A5 publication Critical patent/JP2022517407A5/ja
Priority to JP2024167091A priority Critical patent/JP7835461B2/ja
Application granted granted Critical
Publication of JP7587506B2 publication Critical patent/JP7587506B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021541198A 2019-01-18 2020-01-17 ネフローゼ症候群を処置するためのaav遺伝子療法 Active JP7587506B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024167091A JP7835461B2 (ja) 2019-01-18 2024-09-26 ネフローゼ症候群を処置するためのaav遺伝子療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1900702.0A GB201900702D0 (en) 2019-01-18 2019-01-18 Therapy
GB1900702.0 2019-01-18
PCT/GB2020/050097 WO2020148548A1 (en) 2019-01-18 2020-01-17 Aav gene therapy for treating nephrotic syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024167091A Division JP7835461B2 (ja) 2019-01-18 2024-09-26 ネフローゼ症候群を処置するためのaav遺伝子療法

Publications (4)

Publication Number Publication Date
JP2022517407A JP2022517407A (ja) 2022-03-08
JPWO2020148548A5 JPWO2020148548A5 (https=) 2023-01-30
JP2022517407A5 true JP2022517407A5 (https=) 2023-01-30
JP7587506B2 JP7587506B2 (ja) 2024-11-20

Family

ID=65528327

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021541198A Active JP7587506B2 (ja) 2019-01-18 2020-01-17 ネフローゼ症候群を処置するためのaav遺伝子療法
JP2024167091A Active JP7835461B2 (ja) 2019-01-18 2024-09-26 ネフローゼ症候群を処置するためのaav遺伝子療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024167091A Active JP7835461B2 (ja) 2019-01-18 2024-09-26 ネフローゼ症候群を処置するためのaav遺伝子療法

Country Status (8)

Country Link
US (2) US12544460B2 (https=)
EP (2) EP4516915A3 (https=)
JP (2) JP7587506B2 (https=)
CN (2) CN113543814B (https=)
AU (2) AU2020208997B2 (https=)
CA (1) CA3126429A1 (https=)
GB (1) GB201900702D0 (https=)
WO (1) WO2020148548A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201900702D0 (en) 2019-01-18 2019-03-06 Univ Bristol Therapy
GB202003109D0 (en) 2020-03-04 2020-04-15 Univ Bristol Gene therapy
GB202003618D0 (en) 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
GB202009039D0 (en) 2020-06-15 2020-07-29 Univ Bristol Therapy
GB202103470D0 (en) * 2021-03-12 2021-04-28 Univ Bristol Promoter
CN114592052A (zh) * 2022-04-01 2022-06-07 中国人民解放军陆军军医大学第二附属医院 一种肾病综合征患者pdss2致病突变基因及其检测试剂
EP4273243A1 (en) 2022-05-02 2023-11-08 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Nucleic acid constructs and vectors for podocyte specific expression
WO2025072667A2 (en) * 2023-09-29 2025-04-03 University Of Utah Research Foundation Compositions and methods for treating phosphomannomutase 2 (pmm2) deficiency
CN117871216B (zh) * 2024-03-12 2024-06-04 中日友好医院(中日友好临床医学研究所) 一种石蜡标本中肾小球裂隙膜的三维可视化方法
GB202414499D0 (en) * 2024-10-02 2024-11-13 Purespring Therapeutics Ltd Methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
FR2804127B1 (fr) * 2000-01-20 2004-12-24 Inst Nat Sante Rech Med Gene srn1 implique dans le syndrome nephrotique cortico- resistant, proteine codee par ce gene et utilisations diagnostiques et therapeutiques
WO2003082305A1 (en) 2002-04-03 2003-10-09 Naohide Yamashita Drug containing human placenta-origin mesenchymal cells and process for producing vegf using the cells
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2007125723A1 (ja) 2006-04-28 2007-11-08 Osaka University 糸球体スリット蛋白誘導剤
CN120174012A (zh) 2013-10-24 2025-06-20 优尼科Ip有限公司 用于基因治疗神经疾病的aav-5假型载体
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
HK1249534A1 (zh) 2015-04-06 2018-11-02 哈佛大学校长及研究员协会 用於非清髓性预处理的组合物和方法
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
US20190022250A1 (en) 2015-11-06 2019-01-24 National University Corporation Kumamoto University Pharmaceutical composition for preventing or treating heart failure
WO2017144080A1 (en) * 2016-02-23 2017-08-31 Eyeserv Gmbh Gene therapy for the treatment of a disease of retinal cone cells
MX2019001920A (es) 2016-08-19 2019-07-01 Curevac Ag Arn la terapia contra el cancer.
WO2018144709A2 (en) 2017-02-01 2018-08-09 The Trustees Of The University Of Pennsylvania Gene therapy for treating citrullenemia
GB201900702D0 (en) 2019-01-18 2019-03-06 Univ Bristol Therapy
EP4273243A1 (en) 2022-05-02 2023-11-08 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Nucleic acid constructs and vectors for podocyte specific expression

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)